HealthQuill Genetic Disorder
British drugmaker, GSK Plc.’s multiple myeloma drug, Blenrep, reduced the risk of disease progression or death by about 50% when compared to a standard-of-care combination, according to the company.
Drugs Health

India grapples with thalassaemia crisis with 42 million carriers

HQ Team May 8, 2025: As the world observes World Thalassaemia Day on May 8, India faces a harsh reality—it is often called.

Read More
Merck & Co’s drug, for treating adult patients with kidney and pancreatic cancer, tumours, and who had prior treatment, has been “conditionally” approved by the European Commission, according to a company statement.
Drugs Health Medical

EC grants ‘conditional’ nod for Merck’s drug to treat VHL disease

HQ Team February 18, 2025: Merck and Co’s drug, for treating adult patients with kidney and pancreatic cancer, tumours and who had prior.

Read More
Britain’s National Health Service will provide a gene therapy that may cure sickle cell disease for patients 12 years and older, according to a National Institute for Health and Care Excellence (NICE) statement.
Drugs Health Medical

UK’s NHS to provide gene therapy that may cure sickle cell  disease in adults

Britain’s National Health Service will provide a gene therapy that may cure sickle cell disease for patients 12 years and older, according to.

Read More
IntraBio Inc, a biotechnology company focused on rare and neurodegenerative diseases, got the US regulator’s nod for a drug to treat a certain type of Niemann-Pick disease in adults and pediatric patients weighing about 15 kilograms.
Drugs Health Pharma

IntraBio Inc.’s drug for neurogenerative disorder gets US regulator’s nod

IntraBio Inc, a biotechnology company focused on rare and neurogenerative diseases, got the US regulator’s nod for a drug to treat a certain.

Read More
The Food and Drug Administration has cleared X4 Pharmaceutical’s drug to treat a rare genetic disease that occurs in one in five million births.
Drugs Health Pharma

X4 Pharmaceutical’s drug to fight WHIM syndrome gets green light

HQ Team April 30, 2024: The Food and Drug Administration has cleared X4 Pharmaceutical’s drug to treat a rare genetic disease that occurs.

Read More